Sponsored Content for Colin La Galia

ASX-listed PharmAust subsidiary, Epichem, has entered into a multi-year license agreement to harness “Oxidative Hydrothermal Dissolution” technology from IP owner, Illinois-based Thermaquatica. Epichem will research, develop and promote Thermaquatica's disruptive waste to fuels technology that uses waste and biomass as a feedstock. The company will also target government grant funding to accelerate its research and development initiative.

PharmAust subsidiary Epichem has entered into a joint venture deal to develop a “disruptive” waste-to-fuels technology using biomass and feedstock. Under the 50:50 agreement, medicinal and synthetic chemistry group Epichem and new JV partner Obsidian Minerals will set up the Perren company with the aim of developing and commercialising the biomass/feedstock oxidative hydrothermal dissolution chemical process that can turn waste into fuels.